By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Insider activity at Arcutis Biotherapeutics, Inc. has been all selling for a year now: about $16.2 million from 11 sellers, and zero buyers on the open market.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
On the institutional side, 272 funds reported holding ARQT at the end of Q2 2026, and funds were split between buying and selling. ARQT also shows up in congressional disclosures: 3 reported trades from one lawmaker in two years. 7 quarters in a row of net selling by insiders. Insiders bought in 1 of the last 7 full quarters.
Are insiders buying or selling ARQT stock?
In the last 12 months Arcutis Biotherapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $16.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ARQT?
The most recent open-market insider trade in ARQT was filed on 2026-09-18.
How many institutions own ARQT?
272 investment managers reported holding ARQT in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ARQT?
Yes. Members of Congress reported 3 trades in ARQT over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).